What is Zacks Research’s Estimate for Alkermes Q1 Earnings?

Alkermes plc (NASDAQ:ALKS) – Research analysts at Zacks Research boosted their Q1 2025 earnings per share (EPS) estimates for shares of Alkermes in a research report issued on Wednesday, March 5th. Zacks Research analyst R. Department now forecasts that the company will earn $0.29 per share for the quarter, up from their prior forecast of $0.22. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q2 2025 earnings at $0.35 EPS, Q3 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.42 EPS, FY2025 earnings at $1.35 EPS, Q1 2026 earnings at $0.25 EPS, Q2 2026 earnings at $0.34 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.36 EPS and FY2026 earnings at $1.19 EPS.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%.

ALKS has been the topic of several other reports. The Goldman Sachs Group increased their target price on Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Mizuho raised their target price on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, UBS Group raised shares of Alkermes from a “sell” rating to a “neutral” rating and raised their target price for the stock from $21.00 to $38.00 in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.33.

Alkermes Trading Down 0.9 %

Shares of ALKS opened at $34.35 on Friday. The firm has a market capitalization of $5.59 billion, a P/E ratio of 15.83, a price-to-earnings-growth ratio of 2.20 and a beta of 0.62. The stock’s fifty day simple moving average is $31.85 and its 200 day simple moving average is $29.62. Alkermes has a twelve month low of $22.90 and a twelve month high of $36.45.

Insider Activity

In related news, Director Cato T. Laurencin sold 2,691 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the sale, the director now owns 23,013 shares of the company’s stock, valued at $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Craig C. Hopkinson sold 61,151 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $32.07, for a total value of $1,961,112.57. Following the sale, the executive vice president now directly owns 47,576 shares in the company, valued at approximately $1,525,762.32. The trade was a 56.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 309,179 shares of company stock valued at $10,412,450. Insiders own 4.89% of the company’s stock.

Institutional Investors Weigh In On Alkermes

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Alkermes by 0.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,032 shares of the company’s stock worth $2,877,000 after purchasing an additional 311 shares in the last quarter. CIBC Asset Management Inc raised its holdings in Alkermes by 4.4% during the fourth quarter. CIBC Asset Management Inc now owns 9,155 shares of the company’s stock worth $263,000 after purchasing an additional 384 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Alkermes by 3.9% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 14,203 shares of the company’s stock worth $408,000 after purchasing an additional 532 shares in the last quarter. Nicollet Investment Management Inc. raised its holdings in Alkermes by 1.7% during the third quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock worth $1,227,000 after purchasing an additional 714 shares in the last quarter. Finally, KBC Group NV raised its holdings in Alkermes by 18.8% during the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after purchasing an additional 774 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.